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p97 is a “segregase” that plays a key role in numerous ubiquitin (Ub)-
dependent pathways such as ER-associated degradation. It has been
hypothesized that p97 extracts proteins from membranes or macro-
molecular complexes to enable their proteasomal degradation; how-
ever, the complex nature of p97 substrates has made it difficult to
directly observe the fundamental basis for this activity. To address
this issue, we developed a soluble p97 substrate—Ub-GFP modified
with K48-linked ubiquitin chains—for in vitro p97 activity assays. We
demonstrate that WT p97 can unfold proteins and that this activity is
dependent on the p97 adaptor NPLOC4-UFD1L, ATP hydrolysis, and
substrate ubiquitination, with branched chains providing maximal
stimulation. Furthermore, we show that a p97 mutant that causes
inclusion body myopathy, Paget’s disease of bone, and frontotem-
poral dementia in humans unfolds substrate faster, suggesting that
excess activity may underlie pathogenesis. This work overcomes a
significant barrier in the study of p97 and will allow the future dis-
section of p97 mechanism at a level of detail previously unattainable.
AAA ATPase | Cdc48 | Npl4 | Ufd1 | Proteasome
The AAA ATPase p97, also called valosin-containing protein(VCP) or Cdc48 in yeast, is integral to a wide array of processes
in the cell (1, 2). Its role in ER-associated degradation (ERAD) is
the most well-studied, in which it functions to pull misfolded pro-
teins from the ER membrane so they can be degraded by the pro-
teasome (3). Other degradative pathways with substrates embedded
in large structures, such as ribosome-associated degradation and
mitochondrial-associated degradation, also rely on the activity of p97
(4–6). Furthermore, p97 is involved in nondegradative pathways like
Golgi and nuclear envelope reassembly after mitosis and endosomal
trafficking (7, 8). The common mechanism that underlies all these
cellular jobs is presumed to be the extraction and unfolding of
ubiquitylated proteins by p97 (9, 10). Its homology to other AAA
ATPases that have demonstrated unfolding activities, such as the
proteasome 19S regulatory particle (11, 12), ClpA (13), and VAT
(14, 15), further support the model of p97 as an unfoldase. Although
p97 has been shown to extract proteins from membranes and DNA,
its ability to unfold a protein has not been explicitly demonstrated.
Because of this considerable gap in our knowledge, the biochemical
activity that underlies p97’s myriad functions remains a mystery.
Despite our poor molecular understanding of exactly what
p97 does and how it does it, structural studies and indirect assays
have provided some insight into p97 activity. p97 is a homo-
hexamer, with each protomer comprising an N-domain, two
ATPase domains (D1 and D2) stacked one upon the other, and
an unstructured C-terminal tail (16–18). Although both ATPase
domains are functional, it is thought that hydrolysis of ATP in
D2 is the main driver of mechanical force and ATP binding in
D1 promotes hexamer formation (19–25). The conformations of
the two ATPase domains and the N-domain with respect to one
another are highly cooperative and dependent upon nucleotide
binding and hydrolysis (17, 18, 20, 22, 26–32). Recent high-
resolution structural studies show movement of D2 relative to
N-D1 upon ATP binding in D2, whereas the N domains move
from a coplanar to an axial position with respect to D1 upon ATP
binding to D1 (18). It is unclear how these conformational changes
translate to mechanical force for remodeling protein substrates.
Homologs like ClpA function by threading polypeptides through
the central pore (33), and, even though p97 lacks the requisite
hydrophobic pore residues in D1, other pore residues interact with
and are key to the processing of substrates (19, 34). However,
structural studies imply that the central pore of p97 may be too
narrow to accommodate a polypeptide (16, 18). Other proposed
mechanisms include unfolding by D2 through the arginine “de-
naturation collar” and unfolding outside of the pore by the
movement of the N-domains, similar to what has been proposed
for NSF (34, 35). Resolution of the key question of how p97 works
has been stymied by the lack of a direct assay to measure the core
biochemical activity underlying its “segregase” function.
In performing its biological functions, p97 does not act alone but
instead associates with a set of adaptor proteins that act to recruit or
modify substrates (36). Many of the adaptors contain ubiquitin
(Ub)-binding domains or can add or remove ubiquitin modifica-
tions, thereby linking p97 to ubiquitin signaling (36, 37). Some
adaptors also modulate p97 ATPase activity (38–40). Whereas a
few adaptors have been linked to specific pathways or substrates (8,
41–44), the functions of others remain unknown (36, 37). The best-
characterized p97 adaptor is the heterodimer of NPLOC4/Npl4 and
UFD1L/Ufd1 (UN), which recruits substrates in ERAD and other
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proteasome-dependent degradative processes (45–47). NPLOC4
and UFD1L each bind ubiquitin chains, with UFD1L showing
specificity for K48-linked chains (25, 48, 49). They interact with
p97 at separate sites to form a complex with the stoichiometry of
one UN heterodimer per p97 hexamer (39, 46, 50–52).
A significant incentive to gaining a deeper understanding of
p97’s mechanism of action is the deep connection between this
protein and human disease and possibly cancer therapy. Human
p97 is mutated in the inherited, autosomal-dominant multisys-
tem proteinopathy known as inclusion body myopathy associated
with Paget disease of bone and/or frontotemporal dementia
(IBMPFD) (53, 54). In addition, a small fraction of patients with
inherited amyotrophic lateral sclerosis (ALS; also known as Lou
Gehrig’s disease) also carry mutations in p97 that overlap with
those seen in patients with IBMPFD (54, 55). However, the
mechanism of pathogenesis is not understood in either case. It
has been suggested at various times that pathogenesis arises from
a failure of autophagy, endosomal sorting, clearance of leaky
lysosomes, mitochondrial homeostasis, or mTOR regulation (8,
56–61). Regardless of the cellular target, the molecular-level
defect remains obscure. It has been suggested that failure of
mutant p97 to bind UBXN6/UBXD1 is key (8), but IBMPFD
mutants also show increased binding of UN (62). The mutations
that cause IBMPFD all fall within the N-D1 domain interface
and affect the relative orientation of these domains (63–66).
Moreover, the mutations cause elevated ATP hydrolysis (20, 63–65,
67), but it has been suggested that this is an indirect consequence of
a decoupling of substrate binding from mechanochemical trans-
duction in the D2 domain (54, 68). Because p97 is a hexamer, it has
been unclear how to interpret the autosomal-dominant nature of
IBMPFD. Is this truly the result of enhanced activity, or do the
mutations actually cause reduction of function through a dominant-
negative mechanism, with mutant protomers poisoning mixed
hexamers? Studies in Drosophila support the idea that the patho-
genesis of IBMPFD mutations stems from elevated p97 activity,
resulting in increased processing of TDP-43 (69) and mitofusin (61).
As of yet, there remains no biochemical assay that measures p97’s
presumed core function of protein unfolding that would enable a
direct test of this hypothesis in a defined system.
The nature of the majority of known p97 substrates—unstable,
scarce, modified by ubiquitin, and not readily divorced from their
contexts—presents challenges for studying the enzymatic activity
of p97 in a systematic manner. A major barrier to progress has
been the absence of a simple, rapid, quantitative assay that uses
defined components and can be used to dissect in detail the
mechanism of action of p97. To address this obstacle, we have
developed a soluble, monomeric p97 substrate. Our substrate is
based on a noncleavable ubiquitin fusion protein, UbG76VGFP,
which is targeted for proteolysis by the ubiquitin fusion degra-
dation (UFD) pathway (70). Normally, ubiquitin fusions are
cotranslationally cleaved by a deubiquitinating enzyme to
remove the ubiquitin (71). However, if the C-terminal glycine is
mutated, processing is blocked and the fusion is rapidly de-
graded. Previous studies have demonstrated that the degradation
of these noncleavable ubiquitin fusion proteins, including
UbG76VGFP, is dependent upon p97•UN in human, Drosophila,
and yeast cells (19, 47, 70, 72). We show that p97 can unfold
UbG76VGFP modified with a K48-linked polyubiquitin chain and
that this reaction is dependent upon the nature of the ubiquitin
chain, UN, and p97 ATPase activity in D2. Our system provides a
direct demonstration of a p97 unfoldase activity that depends on
predicted physiological requirements and will be an invaluable
tool for further study of p97’s mechanism.
Results
Substrate and Assay Design.We chose to pursue the UFD pathway
substrate UbG76VGFP because it is rapidly degraded in a p97-
dependent manner in yeast, Drosophila, and human cells (19)
and is a well-behaved protein whose folding state can be easily
monitored by fluorescence. As p97 substrates are often poly-
ubiquitylated, and p97•UN binds polyubiquitin (25), we reasoned
that UbG76VGFP would need to be polyubiquitylated to be rec-
ognized. To efficiently ubiquitylate it, we developed a chimera of
the RING domain from the E3 ubiquitin ligase gp78 and the
E2 enzyme Ube2g2. Prior studies have shown that these enzymes
catalyze formation of K48-linked ubiquitin chains (25). Notably,
these two enzymes function upstream of p97 in ERAD, attesting
to the physiological relevance of the use of these enzymes to
generate a p97 substrate for our assay (73, 74). Compared with
Ube2g2 alone or unfused Ube2g2 with added gp78RING (Fig.
S1A), the gp78RING-Ube2g2 chimera produced unanchored
polyubiquitin chains with very high efficiency (Fig. S1B).
Using this tool, we used various strategies to produce three
types of potential p97 substrates. To simplify notation, linearly
fused proteins are shown by dashes, and the length of the K48-
linked ubiquitin chain attached to a particular ubiquitin is shown
with a superscript preceding the initiator ubiquitin. First, we
aimed to create a substrate with a short ubiquitin chain of de-
fined length. Although the minimal requirement for recognition
of ubiquitylated proteins by p97 is not known, the minimum
ubiquitin chain length for recognition by the proteasome is four
(75). Therefore, we enzymatically ligated Ub3, in which the ubiquitins
were joined via K48 linkages and the distal ubiquitin carried a
K48R mutation, onto the linearly fused ubiquitin to form pure
Ub3Ub-GFP (Fig.1A) (76, 77). Second, to create a substrate with
longer polyubiquitin chains, we built K48-linked chains directly
onto the linearly fused ubiquitin (Fig. 1B). Finally, to produce
substrate with branched ubiquitin chains, we built ubiquitin chains
on a base substrate containing two or more linearly fused ubiquitins
(Ub-Ub-GFP or Ub-Ub-Ub-GFP; Fig. 1C). Heterogeneous sub-
strates were fractionated by size-exclusion chromatography to
enrich for different chain lengths (Fig. 1D).
One concern we had was the potential for GFP to refold after
being processed by p97, leaving the assay without an observable
endpoint. To address this, we added an ATPase mutant of the
chaperonin GroEL. The GroEL D87K “trap” retains the ability
to bind unfolded proteins but can no longer release those pro-
teins (78). This dead-end complex sequesters unfolded GFP,
preventing it from refolding, and has been used previously to
provide assay endpoints for other unfolding machines (13).
GFP Is Unfolded by p97 in a Ubiquitin- and UN-Dependent Manner. To
explore the unfolding potential of p97, we first compared a set of
Ub-GFP substrates bearing K48-linked ubiquitin chains of varying
lengths (Fig. 2A). When mixed with p97, UN, and GroEL (Fig. S2),
Ub-GFP and Ub3Ub-GFP showed no appreciable loss of GFP
fluorescence (Fig. 2B). However, Ub-GFP with both “medium” (>4
ubiquitins; UbMUb-GFP) and “long” (>12 ubiquitins; UbLUb-GFP)
ubiquitin chains showed a modest decrease in fluorescence over
time (∼30%; Fig. 2B). Whereas UbLUb-GFP did show improved
unfolding relative to UbMUb-GFP, the difference was quite small
(∼5% signal loss).
We examined further the requirements for p97-dependent
unfolding by using UbLUb-GFP, as this substrate gave the largest
signal. When incubated with only p97 or p97 and GroEL, no
unfolding was observed (Fig. 2C). A similar result was obtained
when UN was replaced with NSFL1C/p47 or UBXN7/UBXD7,
p97 adaptors involved in Golgi reassembly after mitosis (41) and
regulation of cullin-RING ubiquitin ligases (37, 43, 79), respectively,
despite both of these adaptors binding to p97 and substrate (Fig.
S3). Therefore, UN is required for p97-catalyzed unfolding, and
it cannot be replaced by other adaptors. Additionally, GroEL
was essential to provide an endpoint for the assay. Fluorescence
loss was amplified by the addition of GroEL (Fig. 2C), indicating
that GFP was able to refold to some degree after processing by
p97•UN. However, GroEL did not unfold substrate on its own
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(Fig. 2C), and immunoprecipitation (IP) of GroEL showed that
p97•UN was required for GroEL interaction with substrate (Fig.
2D). Unfolding of substrate by p97 was also highly temperature-
dependent, with the rate and extent of unfolding increasing be-
tween 22 °C and 42 °C (Fig. S4).
We found it curious that ≤40% of the fluorescence signal of
UbLUb-GFP was typically lost in our unfolding assays even
though all components of the system were at or very near satu-
ration (Fig. S5), suggesting that there was another factor influ-
encing substrate competence that remained to be discovered.
Three ubiquitin binding sites with different chain linkage pref-
erences are available on p97•UN (25). Therefore, we tested
whether substrates carrying branched ubiquitin chains would be
more effectively unfolded, because a branch would enable two
separate ubiquitin chains to be elaborated from a single attach-
ment point (in this case, Met1 of GFP). As a proxy for ubiquitin
chains with branched linkages, we expressed Ub-GFP fused to
one or more additional ubiquitins in tandem and used these pro-
teins as substrates for subsequent enzymatic polyubiquitylation (Fig.
3A). Interestingly, a substrate in which K48-linked polyubiquitin
chains were polymerized on Ub-Ub-GFP (UbMUb-UbMUb-GFP)
showed significant improvement in unfolding by p97 compared
with UbMUb-GFP (Fig. 3B) despite the latter having a greater
amount of ubiquitin conjugation as judged by mobility upon SDS/
PAGE (Fig. 3A, lanes 1 and 2). Neither further extension of the
chains to form UbLUb-UbLUb-GFP nor use of a triubiquitin fusion
significantly increased the rate or extent of unfolding (Fig. 3B).
Although we cannot directly visualize ubiquitin chains branching
from each ubiquitin in the Ub-Ub-GFP fusion protein, reactions
run with Ub-K48R indicate that both ubiquitin moieties were ef-
ficiently conjugated with ubiquitin under our reaction conditions
(Fig. S6). Incidentally, this same reaction confirms the linkage
specificity of our Ube2g2–gp78 E2–E3 chimera. Taken together,
our data suggest that the physical arrangement of the ubiquitin
chains is important for unfolding by p97•UN, with the enzyme
preferring substrates with at least one branch point that enables
nucleation of more than one chain of K48-linked ubiquitins.
Substrate Unfolding Is Dependent upon ATP Hydrolysis and
Stimulates p97 ATPase Activity. Next, we examined the energy-
dependence of p97-catalyzed unfolding. UbLUb-UbLUb-GFP was
not unfolded by p97 in the absence of nucleotide, and ADP or
the nonhydrolyzable ATP analog ATPγS could not substitute for
ATP (Fig. 4A). Two p97 ATPase inhibitors, the allosteric in-
hibitor NMS-873 (80) and the D2-specific, ATP-competitive in-
hibitor CB-5083 (81), also prevented ATP-dependent substrate
processing (Fig. 4A). p97 with a D1 domain Walker B motif
mutation (p97-E305Q) that blocks nucleotide hydrolysis but not
binding exhibited only mild defects in substrate unfolding. By
contrast, the same mutation in D2 (p97-E578Q) completely
abolished unfoldase activity (Fig. 4B and Table 1). Together,
these data demonstrate that ATP hydrolysis in D2 powers the
unfolding of substrate by p97•UN.
Some adaptors modulate p97 ATPase activity (38), so we ex-
amined the effects of substrate processing on the hydrolysis of ATP
by p97 and p97•UN. Addition of long unanchored K48-linked
ubiquitin chains (UbLUb), Ub-GFP, Ub3Ub-GFP, or UbLUb-UbL
Ub-GFP did not alter the ATPase activity of p97 (Fig. S7A).
Fig. 1. Substrate design and synthesis. (A) Preassembled, K48-linked Ub3
chains containing a K48R mutation on the distal ubiquitin were ligated onto
a noncleavable linear His6-Ub-GFP fusion protein to produce pure
Ub3Ub-
GFP. (B) E1, E2, ubiquitin, and ATP were added to His6-Ub-GFP to elongate
K48-linked ubiquitin chains of varying lengths on the ubiquitin fused to GFP.
These resulting substrates were purified from free ubiquitin chains via Ni-NTA
resin and crudely fractionated according to chain length via size-exclusion
chromatography to produce pools of “long-”, “medium-”, and “short”-chain
substrates (UbLUb-GFP, UbMUb-GFP, and UbSUb-GFP, respectively). (C) To pro-
duce branched chains, ubiquitin chains of varying length were enzymatically
elongated on a di- or triubiquitin linear fusion protein, Ub-Ub-GFP, or Ub-Ub-
Ub-GFP, similar to B. (D) Size-exclusion chromatogram and corresponding SDS/
PAGE gel for the purification of substrate described in B.
Fig. 2. p97 unfolds Ub-GFP in a UN-dependent manner (A) SDS/PAGE
analysis of GFP substrates with different ubiquitin chain structures stained
with Coomassie Brilliant Blue. (B) Upon addition of ATP, 75 nM p97, 150 nM
UN, and 250 nM GroEL, 25 nM Ub-GFP, and Ub3Ub-GFP did not appreciably
lose fluorescence over time. However, Ub-GFP with “medium” or “long”
K48-linked chains (UbMUb-GFP and UbLUb-GFP) exhibited 26% and 32% loss
of signal after 15 min, respectively. Representative traces shown (n ≥ 3). (C)
Fluorescence of UbLUb-GFP did not change over time with the addition of
p97, GroEL, or p97 plus GroEL. Upon addition of p97 plus UN, a small de-
crease in signal was observed, and this decrease was augmented with the
addition of GroEL. Representative traces shown (n ≥ 2). (D) UbLUb-GFP
coimmunoprecipitated with GroEL only in the presence of p97 and UN.
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Whereas UN did not significantly affect the ATPase activity of p97,
the further addition of UbLUb-UbLUb-GFP stimulated ATP hydro-
lysis by approximately fourfold, whereas Ub-GFP and Ub3Ub-GFP
had no effect (Fig. 4C). The latter result is consistent with the
inability of p97•UN to unfold Ub-GFP or Ub3Ub-GFP. Neither
NSFL1C nor UBXN7 supported substrate-triggered acceleration of
p97 ATP hydrolysis (Fig. S7B). Long, unanchored ubiquitin chains
also stimulated p97 ATPase activity to a similar degree as UbL
Ub-UbLUb-GFP, suggesting that p97 interaction with ubiquitin
chains and not the GFP substrate itself was necessary and sufficient
for the observed acceleration. In agreement with the unfolding re-
sults, the residual ATPase activity of p97-E578Q was unaffected by
substrate plus UN (Fig. 4D). However, p97-E305Q, which was able
to unfold substrate, was also not stimulated by substrate, and even
showed a slight decrease in ATPase activity (Fig. 4D). The E305Q
mutant also showed higher basal ATPase activity than WT, as has
been seen before in steady-state experiments (20). These results
suggest that there is a high degree of cross-talk between ATPase
activity in D1 and D2, and whereas ATP hydrolysis in D2 is the
driving force for unfolding, D1 activity is also needed for substrate-
induced ATPase acceleration.
UN Recruits Substrate to p97. The tight correlation between the
competence of a substrate to be unfolded and its ability to ac-
celerate ATP hydrolysis suggests that binding of substrate to
p97 may stimulate ATPase activity, leading to substrate unfold-
ing. To further probe this hypothesis, we evaluated binding of
substrate to p97. IP of p97 showed that it bound UbLUb-UbLUb-GFP
substrate in the presence but not in the absence of UN (Fig. 5A,
lanes 4 and 5). Reciprocal IP of GFP confirmed that substrate
bound UN in the absence of p97 but did not bind p97 in the ab-
sence of UN (Fig. 5B). Furthermore, the interaction between
p97 and UN appeared to be stabilized by substrate binding (Fig.
5A, lanes 3 and 5). We also analyzed substrate dependence of
GroEL association with p97, but observed high background
Fig. 3. Branched ubiquitin chains are better p97 substrates. (A) SDS/PAGE
analysis of Ub-GFP substrates stained with Coomassie Brilliant Blue. (B)
Comparison of unfolding of substrates with one, two, or three ubiquitins
fused in tandem to GFP. Note that substrate with two linearly fused ubiq-
uitins (e.g., UbMUb-UbMUb-GFP) was unfolded to a greater extent by p97 than
substrate with a single linearly fused ubiquitin even though aggregate ubiquiti-
nation for the latter substrate was at least as extensive or greater than the former.
Addition of an additional linearly fused ubiquitin (UbLUb-UbLUb-UbLUb–GFP) yielded
no further improvement. Representative traces shown (n ≥ 3).
Fig. 4. ATPase activity of p97 is critical for and stimulated by substrate unfolding. (A) Fluorescence traces of UbLUb-UbLUb-GFP in the presence of p97, UN,
GroEL, and various nucleotides and p97 inhibitors. Unfolding was observed only in the presence of ATP. Representative traces shown (n ≥ 2). (B) Unfolding of
UbLUb-UbLUb-GFP by p97 ATPase mutants. p97-E305Q and p97-E578Q are deficient in D1 and D2 ATPase activity, respectively. p97-E305Q was able to unfold
substrate, whereas p97-E578Q was not. Representative traces shown (n ≥ 3). (C) Substrate stimulates ATPase activity of p97 when UN is present. Unanchored
ubiquitin chains and those linked to Ub-GFP yielded equivalent stimulation, whereas Ub-GFP and Ub3Ub-GFP did not stimulate. ATPase activity was measured
with BIOMOL Green as described inMethods and was normalized to basal WT p97 activity. Error bars represent SD (n = 4). (D) Effect of substrate plus UN on
ATPase activity of D1 and D2 domain ATPase mutants. Addition of UbLUb-UbLUb-GFP plus UN slightly decreased ATPase activities of D1 mutant E305Q and
D2 mutant E578Q. Error bars represent SD (n = 4).
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binding to our beads even in the absence of antibody (Fig. 5A, lane
1). The binding signal was increased in lanes 6 and 7 (Fig. 5A), but
this could be the result of p97, which, in our experience, is prone
to exhibit nonspecific binding.
Whereas the unfolding of substrate was highly dependent
on ATP hydrolysis, substrate interaction with p97 was not. IP of
FLAG-UbLUb-FLAG-UbLUb-GFP pulled down equal amounts of
p97 in the absence of added nucleotide and in the presence
of ATP, ATPγS, ATP plus NMS-873, and ATP plus CB-5083
(Fig. 5C). Therefore, p97 does not have to be actively remod-
eling substrate to effectively form a tight complex. Loss of
binding of p97, but not UN, was seen only with added ADP,
which could be the result of the large conformational changes
observed for p97 in its ADP-bound state (18) (Fig. 5C). These
results are consistent with previous studies on Ub chain associ-
ation with p97 and p97•UN (48, 82).
IBMPFD Mutant p97-A232E Has Enhanced Unfoldase Activity. The
autosomal-dominant human syndrome IBMPFD is caused by
mutations that cluster at the interface of the N and D1 domains of
p97. Of the different IBMPFD mutations that have been identi-
fied in p97, A232E exhibits the most severe phenotype in terms of
age of onset and penetrance. In addition, p97-A232E consistently
shows higher basal D2 ATPase rates than WT enzyme (20, 63, 65).
The availability of an assay that directly measures ATP-dependent
unfolding by p97 allowed us to distinguish between two alternative
interpretations of the significance of the enhanced ATPase activity
of the A232E mutant protein. The enhanced activity may reflect a
true gain of function wherein p97-A232E is a more powerful or
faster motor. On the contrary, ATPase activity may increase be-
cause of decoupling of the D2 “motor” from the substrate “load,”
analogous to pushing in the clutch when an engine is revving in
low gear. If the former is more accurate, we would expect to see
increased unfolding by the mutant protein. Conversely, if the latter
is correct, we would expect to see reduced unfolding. The result of
this experiment was unambiguous: p97-A232E exhibited accelerated
unfolding of GFP under the single-turnover conditions used in the
assay (Fig. 6A and Table 1). This effect is reproducible, because, in
two independent sets of preparations, p97-A232E displayed faster
unfolding than WT p97 (Fig. 6 A and C). The substrate-induced
ATPase acceleration observed for WT p97 was also observed with
p97-A232E (Fig. 6B). The mutant protein displays an increased
basal rate of ATP hydrolysis and a higher rate in the presence of
substrate compared with WT.
We identified a reversible, ATP-competitive p97 ATPase in-
hibitor that was recently perfected to yield the clinical candidate
CB-5083 (81), which is in human phase I clinical trials for treat-
ment of cancer. If the basis of IBMPFD pathology is the result of
enhanced unfoldase activity of p97, we reasoned that CB-
5083 could potentially be explored as a therapy for IBMPFD. To
test the feasibility of this idea, we performed unfolding reactions
with p97-A232E at several different concentrations of CB-5083.
Remarkably, when added at 37.5 nM, or one molecule per two
p97 hexamers, CB-5083 normalized the unfolding rate of p97-
A232E to match that of WT (Fig. 6C).
Fig. 5. UN recruits ubiquitylated substrate to p97. (A) Association of substrate
with p97 depends on UN. Reactions containing 100 nM p97, 200 nM UN,
200 nMUbLUb-UbLUb-GFP, and/or 200 nM GroEL were immunoprecipitated by
using an anti-p97 antibody and assessed by Western blot. Substrate was pulled
down with p97 only in the presence of UN, and substrate enhanced the binding
of UN to p97. Effects of substrate and UN on binding of GroEL to p97 could not
be determined as a result of high background binding of GroEL to beads, anti-
body, and/or p97. (B) UN binds directly to substrate and links it to p97. Samples
prepared as in A were immunoprecipitated with an anti-GFP antibody. Substrate
pulled down UN but bound p97 only in the presence of UN. (C) Bound nucleotide
has only a modest effect on formation of a p97•UN•substrate ternary complex.
Samples prepared as in A with various nucleotides and/or p97 inhibitors were
immunoprecipitated by anti-FLAG resin, which bound the FLAG-tagged ubiquitin
on substrate. Binding of p97, but not UN, was reduced only in the ADP state.
Table 1. Rates and extents of unfolding of UbLUb-UbLUb-GFP by
p97 mutants
Mutant Rate, s−1 Plateau, % n
WT 0.195 ± 0.007 33.3 ± 0.8 6
E305Q 0.154 ± 0.005 36.5 ± 0.8 3
E578Q ND ND 3
A232E 0.274 ± 0.007 25.3 ± 0.4 3
The rates and plateaus were calculated by fitting data to a single expo-
nential decay, with the plateau representing the percentage of fluorescence
remaining at the end of the reaction. Unpaired t tests comparing WT rates vs.
those of p97-E305Q and p97-A232E yielded P values of <0.0001 in both cases,
indicating statistically significant differences. Sample size represents number
of technical replicates, and values are shown ± SD. ND, not detected.
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Discussion
P97/VCP is implicated in a broad range of cellular processes in-
cluding membrane fusion, protein trafficking, and ubiquitin-
dependent proteolysis (1). It is thought that the core biochemical
activity of p97 that enables its diverse biological functions is its ability
to act as a segregase that segregates polypeptides from binding
partners in multisubunit complexes, or from large macromolecular
structures including ribosomes, membranes, or chromatin. Although
the mechanism by which p97 exerts segregase activity is not known,
the most economical hypothesis is that it grabs onto the polypeptide
to be segregated and commences to unfold it. However, despite the
appeal of this unifying hypothesis, the ability of WT p97 to harvest
the energy of ATP hydrolysis to unfold a polypeptide has never been
directly demonstrated. We show here, in a well-defined system, that
WT p97 can at least partially unfold a protein. In contrast to prior
studies that used a doubly mutated p97 acting upon an unmodified
protein in the absence of any adaptor (83, 84), the unfolding we
observe exhibits dependencies predicted from prior genetic and
biochemical studies of p97, including dependence on ATP hydrolysis
by the D2 ATPase domain of p97, the heterodimeric adaptor
NPLOC4•UFD1L, and conjugation of an ubiquitin chain to the
substrate that is unfolded (1, 24, 25).
Despite the close alignment of in vitro dependencies reported
here with known in vivo requirements for p97 action, there are two
caveats worth noting. First, we do not know whether the loss of
GFP fluorescence is the result of complete unfolding or local
unfolding. Second, our Ub-GFP model substrate is not a native
substrate of p97. However, p97 activity in the UFD pathway is
absolutely required for its degradation in vivo in yeast, Drosophila,
and human cells (19, 47, 70, 72), and the E2–E3 chimera used to
ubiquitylate Ub-GFP was derived from enzymes that function
directly upstream of p97 in the ERAD pathway (73). Thus, we
believe the reaction reported here represents the essence of p97’s
biochemical activity that underlies its physiological functions.
Processing of our Ub-GFP substrate by p97 is dependent on
the conjugation of multiple ubiquitins connected by K48 link-
ages, which is consistent with reports of K48-linked ubiquitin
chain binding by p97 and UFD1L and linkage-nonspecific chain
binding by NPLOC4 (25, 48, 49, 82). One of our most interesting
findings is that we observed enhanced substrate unfolding when
the substrate contained a branch point enabling the formation of
multiple K48-linked ubiquitin chains. Our substrate contains a
branch at the base of the ubiquitin conjugate, which allows for
two K48-linked chains to be built on a single site of substrate
modification. Because there are multiple ubiquitin binding sites
on the p97•UN complex, the branched chain on our UbLUb-UbL
Ub-GFP substrate may retard, via enhanced avidity, its dissoci-
ation before unfolding. Branched ubiquitin chains can enhance
substrate degradation (85) and have been associated with
p97 previously. Ubiquitin chains with K11 linkages are associated
with multiple p97 adaptor proteins (37) and are implicated in
ERAD (86). Substrates modified with K11 and K11–K48 branched
chains associate with p97•UN and its Drosophila ortholog (87, 88),
and p97 binds K11–K48 branched chains better than either type of
homotypic chain (85). Furthermore, K29 and K48 linkages are
formed on UFD pathway substrates in vivo and in vitro using pu-
rified UFD pathway enzymes (47, 89). Whereas our data with linear
ubiquitin fusions suggest that branched and/or multiple ubiquitin
chains may be important for interaction of substrates with p97•UN,
further work with physiological linkages in vitro and in vivo is
needed to determine the exact requirements for ubquitylated p97
substrates.
The second requirement for p97-catalyzed unfolding is the
heterodimeric adaptor UN. In agreement with prior work, UN
bridges the interaction of substrates with p97 (25, 48). However,
p97 also associates with other adaptor proteins, some of which
(e.g., UBXN7) can cobind with UN and others (e.g., NSFL1C) of
which bind in a mutually exclusive manner (36, 37, 46, 90, 91).
Although there are examples of processes that require UN and
an additional adaptor (42, 92), in general, it is unclear whether
the different adaptors work in different pathways, or work se-
quentially, together, or in opposition to one another in the same
pathway. Mutually exclusive adaptors like NSFL1C bind very
differently from UN yet also promote protein segregation (41,
51, 93). However, neither NSFL1C nor UBXN7 was able to
replace UN in our unfolding assay, suggesting that they promote
substrate processing in a different way or work on different
Fig. 6. IMBPFD mutant p97-A232E is a better unfoldase. (A) In the pres-
ence of UN and GroEL, p97-A232E catalyzed the loss of fluorescence of UbLUb-
UbLUb-GFP faster than WT, suggesting it acts as an improved unfoldase. Rates
are listed in Table 1, and the difference between WT and p97-A232E
is statistically significant at P < 0.0001. Representative traces shown (n ≥
3). (B) p97-A232E shows accelerated ATPase rates in the presence of UN and
substrate. The IBMPFD mutant also had a higher baseline ATPase rate than
WT (unpaired t test, P < 0.0001) and a higher ATPase activity in the presence
of UN and substrate compared with WT (unpaired t test, P = 0.0003). ATPase
activity was measured with BIOMOL Green as described in Methods and
was normalized to basal WT p97 activity. Error bars represent SD (n = 4).
(C) Addition of a 37.5-nM CB-5083 restores p97-A232E unfoldase activity to
WT levels. Representative traces shown (n = 2), and the difference between
WT and p97-A232E rates is statistically significant (unpaired t test, P = 0.02).
Independent preparations of proteins were used for A and C.
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substrates. Our assay provides a platform for further mechanistic
exploration of the functional relationship between different
adaptor proteins.
The final requirement for unfolding of GFP is ATP hydrolysis
by the D2 ATPase of p97. Our results are in direct contrast with a
previous study that showed that p97-dependent unfolding is
inhibited by ATP (94), but are consistent with overwhelming in
vitro and in vivo data (1, 23, 25, 34). Our experiments with
p97 mutants and the D2-specific ATP-competitive inhibitor
CB-5083 demonstrate the importance of D2 ATPase activity over
that of D1, which confirms prior observations (19–25). We ob-
served very little effect of the D1 Walker B mutant on substrate
processing, leaving the role of D1 ATPase activity in p97 function
unclear (1). Not only is the ATPase activity key to substrate
processing, but we also observed its stimulation by ubiquitin chain
or substrate binding. This stimulation was abolished in the D1
Walker B mutant. Nevertheless, this mutant unfolded GFP at
near-WT rates, suggesting that substrate stimulation of ATP hy-
drolysis might not be essential, at least for some substrates.
ATPase acceleration in the presence of the cytoplasmic fragment
of the ERAD substrate Sytl has been previously reported, but,
unlike the stimulation reported here, it was not dependent on UN
or ubiquitylation of the substrate (34), both of which are thought
to be requirements for ERAD. p97 can interact with a substrate
and the ubiquitin chain appended to the substrate (25, 95), sug-
gesting that stimulation of p97 ATPase and perhaps substrate
processing can be regulated through multiple binding interfaces.
Even though we are unable to draw any conclusions about the
mechanism of unfolding by p97, studies on the archaebacterial
homolog VAT support a model whereby substrate is translocated
through the central channel (14, 15), suggesting that adaptor and
substrate engagement must expand p97’s narrow pore (16, 18) to
accommodate the threading of an unfolded polypeptide chain.
Mutations in p97 cause the autosomal-dominant human dis-
ease IBMPFD (53). Prior work has led to conflicting proposals
regarding the underlying basis for pathogenesis in IBMPFD.
Some studies have emphasized a reduction in specific biological
functions of the mutant p97, including its roles in endosomal
trafficking, autophagy, and elimination of leaky lysosomes (8, 56,
60). Defects in these processes have been linked to reduced
binding of mutant p97 to UBXD1 (8). On the contrary, IBMPFD
mutant proteins hydrolyze ATP at a faster rate (20, 63–65).
Whereas it has been speculated that the increase in ATP hy-
drolysis might be the result of an uncoupling of substrate binding
via the N domain to mechanochemical transduction in the D2
domain (54, 68), studies in Drosophila point to an increase in
function for the mutant p97 (61, 67, 69). Furthermore, the
overexpression of WT p97 enhanced IBMPFD mutant pheno-
types whereas inactivation of one copy of WT p97 suppressed
mutant phenotypes, which is consistent with a gain-of-function
mutation (96). The availability of a biochemical assay that di-
rectly measures substrate unfolding, which we propose is the core
biochemical activity underlying p97’s myriad biological functions,
allowed us to investigate this issue. We focused on the mutant with
the most severe disease phenotype, p97-A232E, and observed a
modest but reproducible increase in the rate of substrate unfolding
that was renormalized by addition of an ATP-competitive inhibitor,
implying that the underlying defect in this disease may result in part
from a true gain of function rather than the prevailing loss-of-
function hypothesis. Our results call to mind previous work to en-
gineer Hsp104, in which point mutations greatly augmented its
ATPase and unfoldase activity while altering intersubunit commu-
nication (97). It is interesting that the increased ATPase activity of
p97-E305Q did not cause a similar increase in unfolding rate,
suggesting that the rate of ATP hydrolysis in D2 does not by itself
determine the rate of unfolding. Our experiments were carried out
with pure WT and pure mutant p97, so it will be of interest to study
populations of mixed hexamers of A232E and other IBMPFD
mutants to better recapitulate the situation that pertains in vivo.
Whereas much clearly remains to be done to further investigate this
gain-of-function model, if our proposal is correct, it implies that the
clinical-grade p97 inhibitor (81) that renormalized the activity of the
mutant protein may be useful for therapy of IBMPFD and ALS
cases that arise from mutation of p97.
Methods
A description of previously published proteins used in this study can be found
in Table S1.
gp78RING-Ube2g2 Chimera Construction and Purification. A 72-residue se-
quence of the E3 ubiquitin protein ligase gp78/AMFR (residues 322–393),
containing the RING domain, was fused to the N terminus of the ubiquitin-
conjugating enzyme Ube2g2 with a linker sequence of GTGSH. cDNA
encoding this fusion protein was inserted into the bacterial expression
plasmid p28a-TEV vector to encode a polyHis-tagged protein. Protein was
expressed in BL21(DE3) at 37 °C with 0.4 mM IPTG for 4 h and was purified
on Ni-NTA resin and a Superdex 75 column before being cleaved with TEV
protease overnight at 4 °C. Cleaved protein was then bound to a MonoQ ion
exchange column, eluted with a NaCl gradient (0.05–0.5 M), concentrated
with centrifugal filter units, and flash-frozen.
UbG76VGFP Fusion Construction. The coding sequence for UbG76VGFP in the EGFP-
N1 vector Raymond Deshaies bacteria (RDB) no. 1832] (19) was PCR-amplified and
inserted into pET28a by using NdeI and NotI sites to produce His6-Ub
G76V-GFP
(RDB no. 3006). His6-Ub
G76V-UbG76V-GFP (RDB no. 3344) and His6-Ub
G76V-UbG76V
-UbG76V-GFP (RDB no. 3345) were created by ligating Ub2
G76V and Ub3
G76V, PCR-
amplified from a synthetic Ub4
G76V sequence (RDB no. 2406), into His-UbG76V-GFP
cut with NdeI and HindIII. For simplification, the G76V notation has been left out
of subsequent mentions of these constructs.
Ub3Ub-GFP Synthesis and Purification. A plasmid for bacterial expression of
Ub-K48R (RDB no. 3348) was made from that of Ub (RDB no. 2805) by site-
directed mutagenesis, and the protein was expressed as previously de-
scribed (76). Pure K48-linked Ub3 chains carrying a K48R mutation in the
distal Ub were enzymatically synthesized and purified as described pre-
viously (76, 77). To form Ub3Ub-GFP, 0.5 μM Ube1 (E1), 5 μM gp78RING-
Ube2g2, 2.5 μM Ub-GFP, and 5 μM Ub3 were incubated in 20 mM Hepes,
pH 7.4, 5 mM ATP, and 5 mM MgCl2 overnight at 37 °C. The
Ub3Ub-GFP was
then purified on Ni-NTA resin and a Superdex 200 gel filtration column
before being concentrated with centrifugal filter units and flash-frozen.
Polyubiquitylated Substrate Synthesis and Purification. Reactions were carried
out with final concentrations of 10 μMUb-GFP fusion protein, 1 μM E1, 20 μM
gp78RING-Ube2g2, and 400 μM ubiquitin in 20 mM Hepes, pH 7.4, 10 mM
ATP, and 10 mM MgCl2 at 37 °C overnight. Ubiquitin was added pro-
gressively in small amounts over the first 8 h of the reaction. For FLAG-
tagged substrate, 40 μM FLAG-Ubiquitin (Boston Biochem) was added in
the first 2 h. To purify ubiquitylated GFP from free ubiquitin chains, the re-
action mixture was incubated with Ni-NTA resin, eluted with 300 mM imid-
azole, and run over a Superose 6 size-exclusion column in 20 mMHepes, pH 7.4,
250 mM KCl, 1 mMMgCl2, 1 mM tris(2-carboxyethyl)phosphine (TCEP), and 5%
glycerol. Fractions were pooled into long, medium, and short chain-length
samples, concentrated with centrifugal filter units, and flash-frozen.
ATPase Assays. The ATPase assay protocol was modified from previously
published methods (40). In an untreated microplate (no. 655101; Greiner Bio-
One), 40-μL solutions containing 30 nM p97 hexamer, 150 nM adaptor, and/
or 150 nM substrate in ATPase assay buffer (25 mM Hepes, pH 7.4, 100 mM
KCl, 3 mM MgCl2, 1 mM TCEP, 0.1 mg/mL ovalbumin) were preincubated at
37 °C for 10 min. To this, 10 μL of a 1-mM ATP solution was added, and the
reaction was incubated at 37 °C for 5 or 10 min. After cooling on ice for 30 s,
50 μL of BIOMOL Green reagent (Enzo Life Sciences) was added. Solutions
were developed at room temperature for 30 min before being read at
600 nm. The amount of inorganic phosphate in each sample was calculated
from a standard curve, and relative ATPase activity for a sample was calcu-
lated by normalizing its measurement to that of samples of WT p97 alone.
Fluorescence Unfolding Assays. Unless specified, all assays were carried out at
37 °C. Samples contained 25 nM GFP substrate, 75 nM p97 hexamer, 150 nM
adaptor (UN, NSFL1C, or UBXN7), and/or 250 nM GroEL trap in unfolding assay
buffer (25 mMHepes, pH 7.4, 100 mM KCl, 5 mMMgCl2, 1 mM TCEP, 2 mMATP).
Control experiments indicated that the levels of p97, adaptor, and GroEL used
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were at or near saturation (Fig. 2 and Fig. S5). Other nucleotides and p97 inhib-
itors were present at 2 mM and 10 μM, respectively, when indicated. Kinetic
experiments were carried out on a Fluoro-Log 3 (Horiba Jobin Yvon) with exci-
tation at 488 nm and emission at 509 nm. Relative fluorescence was calculated by
normalizing the fluorescence signal to that at time 0. Unfolding rates were cal-
culated by fitting curves to an exponential decay model in Prism (GraphPad).
Binding Assays.Antibodies used for IP andWestern blotting are listed in Table
S2. Samples containing 100 nM p97, 200 nM UN, 200 nM GFP substrate, and/
or 200 nMGroEL trap in binding assay buffer (25 mMHepes, pH 7.4, 100mMKCl,
3 mM MgCl2, 1 mM TCEP) in a volume of 200 μL were preincubated at 37 °C
for 15 min. Triton X-100 interfered with binding of substrate to GroEL trap,
so 0.01% Triton X-100 was included in all buffers only in reactions that did
not contain GroEL. Nucleotides and inhibitors were present at 2 mM and
10 μM, respectively, where indicated. For IPs that used Protein G magnetic
beads (Bio-Rad Laboratories), protein mixtures were incubated with 1 μL of
antibody for 15 min at 37 °C before a 1-h incubation with 25 μL of beads at
room temperature. For FLAG IPs, reactions were incubated with 25 μL of
anti-FLAG resin (Sigma-Aldrich) for 15 min at room temperature. Following
incubation, all beads were washed three times with 750 μL assay buffer
before being boiled in 50 μL 2× SDS/PAGE loading dye. Samples were then
analyzed by Western blot.
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